Hollis-Eden And Adeona Shares Soar On Mid-Stage Clinical Results - sourced PicksThatMove.com
Hollis-Eden Pharmaceuticals Inc., Adeona Pharmaceuticals Inc.
Calgary, AB 11/13/2009 04:35 PM GMT (TransWorldNews)
Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles. Please visit us at PicksThatMove.com to view more of our profiled stocks.
Hollis-Eden And Adeona Shares Soar On Mid-Stage Clinical Results
The hot stock information of the day includes: HEPH, AEN
Hollis-Eden Pharmaceuticals Inc. (NASDAQ:HEPH) bound 23.22% up to $0.59 on news the company is set to unveil results of their ongoing Phase I/II clinical study of Apoptone for hormone-resistant prostate cancer, at the American Association for Cancer Research - Molecular Targets and Cancer Therapeutics Conference in Boston on November 16th. Hollis-Eden Pharmaceuticals also has clinical trials for its oral Type 2 diabetes candidate Triolex. A phase II trial of this drug is expected to be completed in the first quarter of 2010. Headquartered in San Diego, California, Hollis-Eden Pharmaceuticals Inc is a development stage pharmaceutical company, which accelerates the discovery and development of treatments for autoimmune and metabolic diseases and disorders.
Adeona Pharmaceuticals Inc. (AMEX:AEN) jumped 31.15% up to $0.763 on news the company’s experimental rheumatoid arthritis drug candidate demonstrated significant positive results compared with a placebo in a Phase 2 study, sending its shares soaring in morning trades. Based in Ann Arbor, Michigan, Adeona Pharmaceuticals Inc is a development-stage pharmaceutical company conducting awareness campaigns and advancing the diagnosis, prevention, and treatment of zinc deficiency and chronic copper toxicity in the aging population. The company is developing late-stage drug candidates for rheumatoid arthritis and multiple sclerosis. The company is also developing Trimesta, an anti-inflammatory estrogen agent in Phase 2 clinical trials for the treatment of post-menopausal hot flashes; and Oral Flupirtine, a non-opiate non-addictive oral therapy for the treatment of fibromyalgia and other ophthalmic indications.
To be kept up to date on all of our hot stock information join us at Picks That Move.
About PicksThatMove.com:
PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. We recommend Due Diligence before investing in any stock.
Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/. Feel free to visit our communities on Facebook and Twitter
info@picksthatmove.com
picksthatmove.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
HEPH
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
